Navigation Links
Clinical Data Demonstrates Long-Term Safety of Boston Scientific's Alair[TM]Bronchial Thermoplasty System
Date:9/26/2011

d and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; new product performance; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

1. ERS abstract number 3930; presentation number 3422.

Media Contacts

Sabrina Gomersall, Director, WCG +44(0)203-008-7978, alair@wcgworld.com

Simonetta Balbi, PR Manager Europe, Boston Scientific +39(0)338-793-6422,

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
2. New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
3. Uptake Medical Receives CE Mark for InterVapor - Endoscopic Lung Volume Reduction for Treatment of Severe Emphysema - and Announces Positive Clinical Results
4. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
5. AccuNurse Delivers Real-Time Care Plan Functionality and New Dashboard to Monitor Clinical Trends, Performance and Compliance
6. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
7. Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
8. OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial
9. Genesis Biopharma Adds Cell Therapy Bioprocess Engineering, Clinical Trial Design, Biostatistics, Regulatory Affairs and FDA Compliance Expertise
10. ClinStar to Present on Russias Performance as an Emerging Market in Global Clinical Trials
11. Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Following a bipartisan vote ... moved H.R. 284, the Medicare DMEPOS Competitive Bidding ... for Homecare (AAHomecare) released a statement praising the ... pass the legislation. "Today,s mark-up of ... Ways and Means Committee is a critical step ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Inc. (Nasdaq:GILD) today announced that Study 103, ... once-daily,anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or ... for chronic hepatitis B virus,(HBV) infection, met ... Viread is non-inferior to the company's once-daily ...
... study demonstrates 75% of patients receiving highest ... June 25, 2007 /PRNewswire-FirstCall/ -- According to,findings ... of the,American Diabetes Association (ADA) in Chicago, ... dose of human,GLP-1 analog under development by ...
Cached Medicine Technology:Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
(Date:2/28/2015)... 28, 2015 Kaylie Corrigan, Outdoor Supervisor ... center , and current student obtaining her Masters degree ... a weekly forum in psychoeducation on substance use for ... AZ as part of her studies. , “Even though ... support and counseling at the high school and junior ...
(Date:2/28/2015)... February 28, 2015 Developers of FCPX ... a new overlay plugin for Final Cut Pro X entitled ... “FCPX Overlay Chromatic gives users total control over 6k lens ... CEO of Pixel Film Studios. “FCPX Overlay Chromatic was professionally ... to use interface.” , FCPX Overlay Chromatic Grunge 6K is ...
(Date:2/28/2015)... The World Scout League Commission (WSLC), ... potential EMTs and firefighters, recently announced its decision to ... to raise charitable donations for age-related research. The five-kilometer ... be held on March 29, 2015; registration will start ... 3:30 p.m. , To participate in the race, ...
(Date:2/27/2015)... Santa Clara, CA (PRWEB) February 27, 2015 ... Integrated Passive Devices (IPD), has introduced miniature, wire bondable, ... Brightness and Power LED markets. The ESD88NP ... high transient currents away from sensitive LED and IC ... compared to Multilayer Varistors (MLV). All devices meet ...
(Date:2/27/2015)... Bethesda, MD (PRWEB) February 27, 2015 ... Foundation (Meso Foundation) and the National Cancer Institute ... Malignant Mesothelioma at the National Institutes of Health ... parts: one part is dedicated to medical professionals ... other is directed to the general public, including ...
Breaking Medicine News(10 mins):Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3
... no hair in a world,obsessed with hair is a ... Bald Girls Do Lunch, a not-for-profit organization, is bringing,women ... Los Angeles and,San Diego., At lunches in cities ... who struggle to keep their condition a secret, which,she ...
... Purchasing ... Healthcare Gift Card, PITTSBURGH, Dec. 26 Highmark Inc., the ... first,newborns with Prepaid Healthcare Visa(R) Gift Cards, Highmark,s newly,announced product that ... with, among other life events, the arrival of a,new child. Parents ...
... Among breast cancer patients, both chemotherapy and tamoxifen independently reduced ... breast, according to a study published online December 25 in ... risk reduction persisted for at least 10 and 5 years, ... developing cancer in the other breast is two to six ...
... already known to be more common in Ashkenazi Jewish ... young African-American women with breast cancer, according to one ... date. , Researchers at the Stanford University School of ... finding from a study of 3,181 breast cancer patients ...
... season brings means taking things as they come, expert says ... heightened expectations, financial and social stress, and memories of lost ... of that can lead to seasonal blues during the holidays, ... example, people who expect difficult relationships to improve just because ...
... N.J., Dec. 24 QMed, Inc., (Nasdaq:,QMED) today announced ... for the last 30 business days, the bid price ... $1.00 per share requirement for,continued inclusion under Marketplace Rule ... (8) (D), the Company,will be provided 180 calendar days, ...
Cached Medicine News:Health News:Bald Women Get Their Heads Together in Southern California 2Health News:Highmark to Present State's Newest Residents with Healthcare Gift Cards 2Health News:Breast cancer gene mutation more common in Hispanic, young black women, Stanford/NCCC study finds 2Health News:Breast cancer gene mutation more common in Hispanic, young black women, Stanford/NCCC study finds 3Health News:Realistic Expectations Help Ward Off Holiday Depression 2Health News:QMed, Inc. Receives NASDAQ Letter 2
... CDI creates a smoother fit in the ... patient. The padded continuous hook and eye ... and the extra strong, yet very thin ... as a reinforced open crotch, gripper lace ...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
Short Girdle, Mid-thigh, Front Closure...
Medicine Products: